MateraCor Announces New Appointment to the Board of Directors
Juliana Elstad, MBA becomes fifth Company Director
Aliso Viejo, CA, December 8, 2020. MateraCor, Inc., a medtech start-up developing novel and practical approaches to prevent and reverse advanced heart failure, announced the appointment of Juliana Elstad, MBA to the Board of Directors. Juliana is a CEO, entrepreneur, and advisor with over 20 years of experience in small startup to multi-billion-dollar environments. Her expertise in strategic planning, business development, financing, and marketing will add significant capabilities to the MateraCor Board. Juliana has unique success track record of both achieving start-up exits and leading investments and acquisitions on the behalf of a strategic player. Juliana has been President and CEO of Impleo Medical. She is currently a Board Member of AdvaMed Accel, the division of AdvaMed focused on the smaller innovative companies. Previously, she had leadership roles at Intelect Medical (acquired by Boston Scientific), NDI Medical, Medtronic, and others. Before her 17 years at MedTech industry, she was a management consultant with McKinsey & Company. Juliana holds an MBA from the Wharton School of University of Pennsylvania and a Master in Economics from Moscow State Institute of International Relations.
Frank Ahmann, President & CEO of MateraCor, stated that “Juliana Elstad brings a unique skill set and experience to supervise, advice, and guide the Company as it enters a rapid growth phase towards validation of its heart failure therapies.” Juliana Elstad replied that “I am eager to contribute to the development of MateraCor considering the Company’s significant technical and clinical capabilities and the huge potential for its therapeutic products to improve the lives and prognosis of heart failure patients with a practical and cost-effective procedure.”
MateraCor, Inc. is a Southern California – based start-up developing novel approaches to prevent progression and reverse heart failure, the chronic debilitating condition that represents the most common hospitalization cause in the elderly population with a poor prognosis of 50% survival within 5 years of diagnosis. MateraCor’s lead product, Trans-Catheter Myocardial Restoration (TCMR), consists of an implantable hydrogel and a minimally invasive endocardial delivery system to treat ischemic or non-ischemic heart failure with reduced ejection faction. Injected directly into the damaged heart muscle, the hydrogel reduces cardiac stress and reshapes the ventricle leading to marked improvements in exercise capacity and patient well-being. TCMR is an investigational device not approved for sale.
MateraCor Expands Leadership Team
Aliso Viejo, CA, November 16, 2020. MateraCor, Inc., a medtech start-up developing novel and practical approaches to prevent and reverse advanced heart failure, announced the addition of J. Alan Crunkleton, MD, Ph.D. to the management leadership team as Chief Operating Officer.
Dr. Crunkleton is a highly seasoned entrepreneur whose hands-on experience spans all strategic and operational aspects of start-up companies from foundation to exit. He has a successful track record translating market needs and opportunities into products and rapidly establishing regulatory approvals, reimbursement channels, and global distribution. As CEO of Trifoil Imaging, he led the successful turnaround of this preclinical imaging company after he founded and led Correx, Inc., a minimally invasive aortic stenosis device company, and Boreas, Inc., a start-up that commercialized 4.2-Kelvin cryogenic cooler technology and was acquired by a global partner. Alan holds a Ph.D. in mechanical engineering from Massachusetts Institute of Technology as well as an MD from the University of Massachusetts.
“We are delighted to have Alan join the MateraCor team and expect him to be a major contributor as we transition to the clinical stage of development of our lead candidate. Alan is already demonstrating his strategic planning and execution skills,” stated Frank Ahmann, President & CEO. Dr. Crunkleton remarked that “proving the value of MateraCor’s heart failure device therapy will require superb execution considering the huge potential but also the complexities of advanced heart failure. I am excited to contribute to this effort in fundamentally improving the heart failure patients’ lives.”
For more news, follow us on paperstreet.vc or on LinkedIn…